公司簡介

江蘇眾紅生物工程創藥研究院有限公司(簡稱“眾紅生物”)是由常州千紅生化制藥股份有限公司(深交所上市代碼:002550;簡稱:千紅制藥)和國家“千人計劃”特聘專家領銜的國際聯合研發團隊2011年8月共同投資創建位于江蘇省常州市國家級高新技術開發區的獨立法人單位。是一家集創新的生物醫藥研發技術、先進的管理運作模式、和諧的企業文化理念為一體的創新研發型生物醫藥企業。眾紅生物2015年被人社部和全國博士后管委會批準設立國家博士后科研工作站,2017年獲批國家高新技術企業。


眾紅生物、京森生物(控股子公司)和晶紅生科(參股子公司),依托自身成熟技術平臺的科研成果轉化能力和產學研融合優勢,依靠由一批國內外知名的生物醫藥專家組成的跨國研發團隊的技術支撐,主要從事具有自主知識產權針對癌癥、心腦血管、內分泌與過敏等為主要適應癥的基因工程蛋白酶類、人源與人源化抗體類和長效修飾蛋白類等創新藥物的研發與轉化,食品安全與臨床診斷試劑和生物醫藥新材料的應用開發、成果轉化和產業化。截止到2018年8月,眾紅生物與其子公司已申請國內和國際發明專利一百多項,其中已獲授權專利數十項。我們力爭將眾紅生物和其子公司建成有良好經濟效益、受同行尊重、具自身特色的現代生物醫藥綜合研發機構和產學研融合集成基地。


ZonHonBio (ZonHon Biopharma Institute, Inc.) located in Changzhou National High-tech Development Zone was co-founded in August 2011 by QianHongBio (Changzhou Qianhong Biopharma Co., Ltd., SZSE: 002550) and an international research and development team led by a State Specially Recruited Expert. ZonHonBio aims to be an independent and innovative bio-pharmaceutical company with advanced biotechnology, progressive management model and congenial enterprise culture. ZonHonBio was approved to set up a postdoctoral programme by the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee in 2015. ZonHonBio was also awarded the title of National High-tech Enterprise in 2017.


Relying on mature technology platform with the transformation capability of scientific research achievements and the advantage of industry-university-research integration, ZonHonBio, GENSUNBIO and GENHONBIO, the holding and participating subsidiaries of ZonHonBio respectively, are mainly engaged in the research and development of innovative drugs such as genetically engineered proteases, human and humanized antibodies and modified long-acting protein medicines targeting for cancer, cardiovascular, endocrine and allergy diseases. We also engage in the application, industrialization and commercialization of food safety and clinical diagnostic reagents and biomedical materials. All the achievements made by our multinational research team composed of well-known biologists and pharmacists have proprietary intellectual property rights. As of August 2018, ZonHonBio and its subsidiaries have applied for more than 100 domestic and international patents, among which dozens have been granted. Our aim is to build a modern biomedical research and development institution as well as an integrated industry-university-research base that is financially successful, respected by peers, and has our own characteristics.



猫咪大香蕉伊在线播放,大香蕉伊在线猫咪av,m猫咪av大香蕉,伊素婉衣服视频在线播放,手机在线观看的a站免费